Literature DB >> 12822836

Effect of proline on creatine kinase activity in rat brain.

Adriana Kessler1, Elisa Costabeber, Carlos Severo Dutra-Filho, Angela Terezinha Souza Wyse, Moacir Wajner, Clovis Milton Duval Wannmacher.   

Abstract

Type II Hyperprolinemia is an inherited disorder caused by a deficiency of delta1-pyrroline-5-carboxilic acid dehydrogenase, whose biochemical hallmark is proline accumulation in plasma and tissues. Although neurologic symptoms occur in most patients, the neurotoxicity of proline is still controversial. The main objective of this study was to investigate the effect of acute and chronic administration of proline on creatine kinase activity in the homogenates of cerebellum and midbrain from Wistar rats. Acute treatment was performed by subcutaneous administration of one injection of proline to 22-day-old rats. For chronic treatment, proline was administered four times a day from the 6th to the 21st postpartum day. The results showed that creatine kinase activity was significantly inhibited in the cerebellum and midbrain of rats subjected to acute proline administration. In contrast, this activity was increased in animals subjected to chronic administration. We also measured the in vitro effect of proline on creatine kinase activity in the same cerebral structures of 22-day-old nontreated rats. Proline significantly inhibited creatine kinase activity. Considering the importance of creatine kinase for the maintenance of energy homeostasis in the brain, it is conceivable that an alteration of this enzyme activity in the brain may be one of the mechanisms by which proline might be neurotoxic.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12822836     DOI: 10.1023/a:1023871204910

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  33 in total

Review 1.  Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders.

Authors:  M A Tarnopolsky; M F Beal
Journal:  Ann Neurol       Date:  2001-05       Impact factor: 10.422

2.  Molecular cloning and expression of a high affinity L-proline transporter expressed in putative glutamatergic pathways of rat brain.

Authors:  R T Fremeau; M G Caron; R D Blakely
Journal:  Neuron       Date:  1992-05       Impact factor: 17.173

3.  A method for the estimation of serum creatine kinase and its use in comparing creatine kinase and aldolase activity in normal and pathological sera.

Authors:  B P HUGHES
Journal:  Clin Chim Acta       Date:  1962-09       Impact factor: 3.786

4.  Creatine kinase activity in postnatal rat brain development and in cultured neurons, astrocytes, and oligodendrocytes.

Authors:  P Manos; G K Bryan; J Edmond
Journal:  J Neurochem       Date:  1991-06       Impact factor: 5.372

5.  On the mechanisms of neuroprotection by creatine and phosphocreatine.

Authors:  N Brustovetsky; T Brustovetsky; J M Dubinsky
Journal:  J Neurochem       Date:  2001-01       Impact factor: 5.372

6.  Effects of amino acids on the isolated chicken retina, and on its response to glutamate stimulation.

Authors:  A Van Harreveld; E Fifkova
Journal:  J Neurochem       Date:  1973-04       Impact factor: 5.372

7.  Regional distribution in rat brain of 1-pyrroline-5-carboxylate dehydrogenase and its localization to specific glial cells.

Authors:  S G Thompson; P T Wong; S F Leong; E G McGeer
Journal:  J Neurochem       Date:  1985-12       Impact factor: 5.372

8.  Proline reduces creatine kinase activity in the brain cortex of rats.

Authors:  Adriana Kessler; Elisa Costabeber; Carlos Severo Dutra-Filho; Angela Terezinha Souza Wyse; Moacir Wajner; Clóvis Milton Duval Wannmacher
Journal:  Neurochem Res       Date:  2003-08       Impact factor: 3.996

9.  Toxicity of L-proline toward rat hippocampal neurons.

Authors:  J V Nadler; A Wang; A Hakim
Journal:  Brain Res       Date:  1988-07-19       Impact factor: 3.252

10.  Effect of proline administration on rat behavior in aversive and nonaversive tasks.

Authors:  J C Moreira; C M Wannmacher; S M Costa; M Wajner
Journal:  Pharmacol Biochem Behav       Date:  1989-04       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.